These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25085789)

  • 1. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.
    Gaykema SB; Schröder CP; Vitfell-Rasmussen J; Chua S; Oude Munnink TH; Brouwers AH; Bongaerts AH; Akimov M; Fernandez-Ibarra C; Lub-de Hooge MN; de Vries EG; Swanton C; Banerji U
    Clin Cancer Res; 2014 Aug; 20(15):3945-54. PubMed ID: 25085789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft.
    Oude Munnink TH; Korte MA; Nagengast WB; Timmer-Bosscha H; Schröder CP; Jong JR; Dongen GA; Jensen MR; Quadt C; Hooge MN; Vries EG
    Eur J Cancer; 2010 Feb; 46(3):678-84. PubMed ID: 20036116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
    Nagengast WB; de Korte MA; Oude Munnink TH; Timmer-Bosscha H; den Dunnen WF; Hollema H; de Jong JR; Jensen MR; Quadt C; Garcia-Echeverria C; van Dongen GA; Lub-de Hooge MN; Schröder CP; de Vries EG
    J Nucl Med; 2010 May; 51(5):761-7. PubMed ID: 20395337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
    Canonici A; Qadir Z; Conlon NT; Collins DM; O'Brien NA; Walsh N; Eustace AJ; O'Donovan N; Crown J
    Invest New Drugs; 2018 Aug; 36(4):581-589. PubMed ID: 29396630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
    Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
    Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.
    Terwisscha van Scheltinga AG; Berghuis P; Nienhuis HH; Timmer-Bosscha H; Pot L; Gaykema SB; Lub-de Hooge MN; Kosterink JG; de Vries EG; Schröder CP
    Eur J Cancer; 2014 Sep; 50(14):2508-16. PubMed ID: 25027745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.
    Wainberg ZA; Anghel A; Rogers AM; Desai AJ; Kalous O; Conklin D; Ayala R; O'Brien NA; Quadt C; Akimov M; Slamon DJ; Finn RS
    Mol Cancer Ther; 2013 Apr; 12(4):509-19. PubMed ID: 23395886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models.
    Jensen MR; Schoepfer J; Radimerski T; Massey A; Guy CT; Brueggen J; Quadt C; Buckler A; Cozens R; Drysdale MJ; Garcia-Echeverria C; Chène P
    Breast Cancer Res; 2008; 10(2):R33. PubMed ID: 18430202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen.
    Kong A; Rea D; Ahmed S; Beck JT; López López R; Biganzoli L; Armstrong AC; Aglietta M; Alba E; Campone M; Hsu Schmitz SF; Lefebvre C; Akimov M; Lee SC
    Oncotarget; 2016 Jun; 7(25):37680-37692. PubMed ID: 27129177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer.
    Dijkers EC; Oude Munnink TH; Kosterink JG; Brouwers AH; Jager PL; de Jong JR; van Dongen GA; Schröder CP; Lub-de Hooge MN; de Vries EG
    Clin Pharmacol Ther; 2010 May; 87(5):586-92. PubMed ID: 20357763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 89Zr-bevacizumab PET imaging in primary breast cancer.
    Gaykema SB; Brouwers AH; Lub-de Hooge MN; Pleijhuis RG; Timmer-Bosscha H; Pot L; van Dam GM; van der Meulen SB; de Jong JR; Bart J; de Vries J; Jansen L; de Vries EG; Schröder CP
    J Nucl Med; 2013 Jul; 54(7):1014-8. PubMed ID: 23651946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.
    Martins CD; Da Pieve C; Burley TA; Smith R; Ciobota DM; Allott L; Harrington KJ; Oyen WJG; Smith G; Kramer-Marek G
    Clin Cancer Res; 2018 Apr; 24(8):1853-1865. PubMed ID: 29437790
    [No Abstract]   [Full Text] [Related]  

  • 14. 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
    Ulaner GA; Hyman DM; Lyashchenko SK; Lewis JS; Carrasquillo JA
    Clin Nucl Med; 2017 Dec; 42(12):912-917. PubMed ID: 28872549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
    Gebhart G; Lamberts LE; Wimana Z; Garcia C; Emonts P; Ameye L; Stroobants S; Huizing M; Aftimos P; Tol J; Oyen WJ; Vugts DJ; Hoekstra OS; Schröder CP; Menke-van der Houven van Oordt CW; Guiot T; Brouwers AH; Awada A; de Vries EG; Flamen P
    Ann Oncol; 2016 Apr; 27(4):619-24. PubMed ID: 26598545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of [
    Dehdashti F; Wu N; Bose R; Naughton MJ; Ma CX; Marquez-Nostra BV; Diebolder P; Mpoy C; Rogers BE; Lapi SE; Laforest R; Siegel BA
    Breast Cancer Res Treat; 2018 Jun; 169(3):523-530. PubMed ID: 29442264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
    McKnight BN; Viola-Villegas NT
    Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
    Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA
    J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Pool M; Terwisscha van Scheltinga AGT; Kol A; Giesen D; de Vries EGE; Lub-de Hooge MN
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1328-1336. PubMed ID: 28315949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using
    Ulaner GA; Lyashchenko SK; Riedl C; Ruan S; Zanzonico PB; Lake D; Jhaveri K; Zeglis B; Lewis JS; O'Donoghue JA
    J Nucl Med; 2018 Jun; 59(6):900-906. PubMed ID: 29146695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.